{"id":"epoetin-zeta","rwe":[{"pmid":"36871229","year":"2023","title":"Three-year safety observation of subcutaneous administration of epoetin-zeta in patients with chronic renal anemia: Results from PASCO II study.","finding":"","journal":"Clinical nephrology","studyType":"Clinical Study"},{"pmid":"33450134","year":"2023","title":"Data from a microdosed recombinant human erythropoietin administration study applying the new biotinylated clone AE7A5 antibody and a further optimized sarcosyl polyacrylamide gel electrophoresis protocol.","finding":"","journal":"Drug testing and analysis","studyType":"Clinical Study"},{"pmid":"32524766","year":"2020","title":"Dose equivalency and efficacy of biosimilar erythropoietin stimulating agents: Data from real clinical practice.","finding":"","journal":"Pharmacology research & perspectives","studyType":"Clinical Study"},{"pmid":"30287621","year":"2019","title":"Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes.","finding":"","journal":"Haematologica","studyType":"Clinical Study"},{"pmid":"29429032","year":"2018","title":"Comparative risk/benefit profile of biosimilar and originator erythropoiesis-stimulating agents (ESAs): data from an Italian observational study in nephrology.","finding":"","journal":"European journal of clinical pharmacology","studyType":"Clinical Study"}],"tags":[{"label":"Biologic","category":"modality"},{"label":"Erythropoietin receptor","category":"target"},{"label":"EPOR","category":"gene"},{"label":"Active","category":"status"},{"label":"Anemia in chronic kidney disease","category":"indication"},{"label":"Hospira UK Limited","category":"company"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"company":"Hospira UK Limited","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=EPOETIN ZETA","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:51:21.381047+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:51:29.338816+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T00:51:21.453389+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=EPOETIN ZETA","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:51:29.803648+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Erythropoietin receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:51:31.149202+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2108593/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:51:30.555860+00:00"}},"allNames":"silapo","offLabel":[],"synonyms":["silapo","epoetin zeta"],"timeline":[{"date":"2007-12-18","type":"positive","source":"DrugCentral","milestone":"EMA approval (Hospira UK Limited)"}],"approvals":[{"date":"2007-12-18","orphan":false,"company":"Hospira UK Limited","regulator":"EMA"}],"brandName":"Silapo","ecosystem":[{"indication":"Anemia in chronic kidney disease","otherDrugs":[{"name":"daprodustat","slug":"daprodustat","company":"Glaxosmithkline"},{"name":"epoetin alfa","slug":"epoetin-alfa","company":"Amgen"},{"name":"methoxy polyethylene glycol-epoetin beta","slug":"methoxy-polyethylene-glycol-epoetin-beta","company":"Hoffman-La Roche"},{"name":"nandrolone decanoate","slug":"nandrolone-decanoate","company":"Aspen Global Inc"}],"globalPrevalence":850000000}],"mechanism":{"target":"Erythropoietin receptor","targets":[{"gene":"EPOR","source":"DrugCentral","target":"Erythropoietin receptor","protein":"Erythropoietin receptor"}],"modality":"Biologic","explanation":"","oneSentence":"","technicalDetail":"Silapo, also known as EPOETIN ZETA, is a recombinant human erythropoietin analogue that binds to the erythropoietin receptor, triggering a cascade of intracellular signaling events that ultimately lead to the proliferation and differentiation of erythroid progenitor cells."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5170","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=EPOETIN%20ZETA","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=EPOETIN ZETA","fields":["publications"],"source":"PubMed/NCBI"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T10:59:19.740971","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:51:32.445292+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"darbepoetin alfa","drugSlug":"darbepoetin-alfa","fdaApproval":"2001-09-17","relationship":"same-target"},{"drugName":"epoetin alfa","drugSlug":"epoetin-alfa","fdaApproval":"1989-06-01","relationship":"same-target"},{"drugName":"methoxy polyethylene glycol-epoetin beta","drugSlug":"methoxy-polyethylene-glycol-epoetin-beta","fdaApproval":"2007-11-14","relationship":"same-target"},{"drugName":"peginesatide","drugSlug":"peginesatide","fdaApproval":"2012-03-27","patentExpiry":"Jun 2, 2026","patentStatus":"Patent protected","relationship":"same-target"}],"genericName":"epoetin zeta","indications":{"approved":[{"name":"Anemia in chronic kidney disease","source":"DrugCentral","snomedId":707323002,"regulator":"FDA","usPrevalence":37000000,"globalPrevalence":850000000,"prevalenceMethod":"curated","prevalenceSource":"Lancet, 2023"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"darbepoetin-alfa","brandName":"darbepoetin alfa","genericName":"darbepoetin alfa","approvalYear":"2001","relationship":"same-target"},{"drugId":"epoetin-alfa","brandName":"epoetin alfa","genericName":"epoetin alfa","approvalYear":"1989","relationship":"same-target"},{"drugId":"methoxy-polyethylene-glycol-epoetin-beta","brandName":"methoxy polyethylene glycol-epoetin beta","genericName":"methoxy polyethylene glycol-epoetin beta","approvalYear":"2007","relationship":"same-target"},{"drugId":"peginesatide","brandName":"peginesatide","genericName":"peginesatide","approvalYear":"2012","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT01543477","phase":"","title":"Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-07-07","conditions":["Renal Anemia","Pregnancy","Lactation"],"enrollment":4501,"completionDate":"2020-04-29"},{"nctId":"NCT03598582","phase":"PHASE4","title":"Biological Predictive Factors of Response to ESA in Low Risk MDS Patients","status":"COMPLETED","sponsor":"Association pour la recherche sur les Affections Malignes en Immunologie Sanguine","startDate":"2013-01-01","conditions":["Myelodysplastic Syndromes"],"enrollment":70,"completionDate":"2018-05-01"},{"nctId":"NCT01626547","phase":"","title":"Biosimilar Retacrit™ (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology","status":"COMPLETED","sponsor":"Hospira, now a wholly owned subsidiary of Pfizer","startDate":"2010-12","conditions":["Chemotherapy-induced Symptomatic Anaemia","Solid Tumours","Malignant Lymphomas","Multiple Myeloma"],"enrollment":291,"completionDate":"2013-07"},{"nctId":"NCT01423955","phase":"PHASE2","title":"Erythropoietin (EPO) to Protect Renal Function After Cardiac Surgery","status":"COMPLETED","sponsor":"Region Skane","startDate":"2011-10","conditions":["Kidney Failure","Renal Failure"],"enrollment":75,"completionDate":"2013-04"}],"_emaApprovals":[{"date":"2007-12-18","status":"Authorised","company":"Hospira UK Limited"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"012680","UMLSCUI":"C1997870","chemblId":"CHEMBL2108593","ChEMBL_ID":"CHEMBL2108593","DRUGBANK_ID":"DB00016","SNOMEDCT_US":"428902004","MESH_SUPPLEMENTAL_RECORD_UI":"C530192"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"Hospira UK Limited","relationship":"Original Developer"}],"publicationCount":34,"therapeuticAreas":["Hematology"],"biosimilarFilings":[],"originalDeveloper":"Hospira UK Limited","recentPublications":[{"date":"2023 May","pmid":"36871229","title":"Three-year safety observation of subcutaneous administration of epoetin-zeta in patients with chronic renal anemia: Results from PASCO II study.","journal":"Clinical nephrology"},{"date":"2023 Feb","pmid":"33450134","title":"Data from a microdosed recombinant human erythropoietin administration study applying the new biotinylated clone AE7A5 antibody and a further optimized sarcosyl polyacrylamide gel electrophoresis protocol.","journal":"Drug testing and analysis"},{"date":"2020 Jun","pmid":"32524766","title":"Dose equivalency and efficacy of biosimilar erythropoietin stimulating agents: Data from real clinical practice.","journal":"Pharmacology research & perspectives"},{"date":"2019 Mar","pmid":"30287621","title":"Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes.","journal":"Haematologica"},{"date":"2018 Jun","pmid":"29429032","title":"Comparative risk/benefit profile of biosimilar and originator erythropoiesis-stimulating agents (ESAs): data from an Italian observational study in nephrology.","journal":"European journal of clinical pharmacology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"Hospira UK Limited","companyId":"hospira-uk-limited","modality":"Recombinant protein","firstApprovalDate":"2007","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:51:32.445292+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}